pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 24·1 min read
save

DC judge dismisses Merck's challenge to Medicare drug price negotiations

Aug 24, 2026·read at Endpoints ↗RegulatoryNegative

A Washington D.C. federal judge rejected Merck's lawsuit contesting Medicare drug price negotiations under the Inflation Reduction Act. Judge Colleen Kollar-Kotelly of the U.S. District Court for the District of Columbia issued the decision after a lengthy review.

The case, filed more than three years ago, sought to block the government’s authority to negotiate prices for certain Merck medicines. The judge’s ruling leaves the challenge without merit and upholds the administration’s pricing program.

The decision is a setback for Merck, which had hoped to limit the impact of negotiated pricing on its revenue. It also signals that similar challenges by other drug makers may face steep judicial hurdles.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “DC judge rejects Merck’s IRA case more than three years after it was filed”

read at Endpoints ↗
85 words · retrieved Aug 24
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 7h agoUnited Therapeutics' legal victory; BMS' Camzyos approved for kidsEndpoints
  • 7h agoIs AI jacking up healthcare costs?Endpoints
  • 8h agoLilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staffEndpoints
  • 9h ago#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapyEndpoints
  • 9h agoQ&A: Anthropic's life sciences team talk Claude's first scientific discoveryEndpoints